Seizures During Radiotherapy for High-grade Gliomas
NCT04552756 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23
Last updated 2025-01-15
Summary
The primary objective of this trial is to evaluate the seizure frequency during a course of radiotherapy for high-grade (grade III or IV) gliomas. The patients keep a seizure diary during and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. At the end of radiotherapy, the patients are asked to complete a questionnaire regarding their satisfaction with the seizure diary.
Progression of seizure activity compared to baseline is defined as increase of frequency of seizures by more than 50%, increase of severity of seizures, or as Initiation or increase anti-epileptic medication by at least 25%. To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, and during the sixth week following radiotherapy.
The main goal of the study is to generate objective data regarding the occurrence, frequency and severity of seizures as well as regarding the use of anti-epileptic medication during the course of radiotherapy for high-grade gliomas. These data are used to evaluate the potential effect of radiotherapy on occurrence of seizures in these patients and generate hypotheses. Therefore, statistical analyses of primary and secondary endpoints focus on descriptive methods. If statistical tests are applied, they are to be interpreted from an exploratory perspective.
Thirty-two patients with documented start of radiotherapy and any documented diary data at baseline and after start of radiotherapy should be subjected to statistical analysis. Assuming that 10% of patients do not fulfil these requirements, a total of 35 patients should be enrolled to this trial. Recruitment should be completed within 12 months.
With this sample size a one-sample binomial test with a one-sided significance level of 2.5% has a power of 80% to yield statistical significance if the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline is 30% (rate under the alternative hypothesis) assuming a 'natural' background progression-rate of 10% without radiotherapy (null hypothesis). If the natural course of the disease would lead to a progression-rate of 5% without radiotherapy only, the power increases to 98%.
Conditions
- High-grade Glioma
Interventions
- DIAGNOSTIC_TEST
-
Seizure Diary
The patients keep a seizure diary during the period of radiotherapy and up to 6 weeks following radiotherapy. Every day, the patients document the number (and type) of seizures and intake of anti-epileptic medication. The seizure diary will be used to assess the rate of patients with progression of seizure events during the course of radiotherapy compared to baseline. To obtain an objective assessment of seizure activity in addition to patient reported outcomes, an electroencephalography (EEG) is performed during the first and the sixth week of radiotherapy, as well as during the sixth week following radiotherapy. Activity typical for epilepsy includes spike waves, sharp waves and/or sharp slow waves and is classified as absent or present.
Sponsors & Collaborators
-
Zealand University Hospital
collaborator OTHER -
University Hospital Schleswig-Holstein
lead OTHER
Principal Investigators
-
Dirk Rades, MD · Department of Radiation Oncology, University of Lübeck, Germany
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2022-04-22
- Completion
- 2022-12-05
Countries
- Germany
Study Locations
More Related Trials
-
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
NCT01222754 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
NCT00978458 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
NCT03243461 ·Status: UNKNOWN ·Phase: PHASE3
-
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
NCT00114140 ·Status: COMPLETED ·Phase: PHASE2
-
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
NCT06894979 ·Status: RECRUITING ·Phase: PHASE1
-
Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
NCT00005602 ·Status: COMPLETED ·Phase: PHASE1
-
Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma
NCT00003916 ·Status: COMPLETED ·Phase: PHASE3
-
Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study
NCT02302235 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
NCT00253448 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00482677 ·Status: COMPLETED ·Phase: PHASE3
-
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT02709226 ·Status: COMPLETED ·Phase: PHASE1
-
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
NCT01089101 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
NCT06368817 ·Status: RECRUITING ·Phase: PHASE2
-
Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas
NCT02970448 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Imaging Study of GC1008 in Glioma
NCT01472731 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
NCT00182819 ·Status: COMPLETED ·Phase: PHASE3
-
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
NCT00042991 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Temozolomide and Radiation Therapy in Treating Young Patients With Pontine Glioma
NCT00514397 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
NCT04623931 ·Status: RECRUITING ·Phase: PHASE2
-
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
NCT03251027 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma
NCT00002806 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
NCT00209989 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00006353 ·Status: COMPLETED ·Phase: PHASE3
-
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
NCT00626730 ·Status: UNKNOWN ·Phase: PHASE2
-
Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma
NCT00472017 ·Status: COMPLETED ·Phase: PHASE1